Bioquímica
Polimorfismos Genéticos
Referencias
- ↑ E Galli y L Feijoo. CITOCROMO P-450 Y SU IMPORTANCIA CLÍNICA (en español). Revista de Neuro-Psiquiatría 2002; 65: 187-201. Último acceso 4 de marzo de 2008.
- Smith G, Stubbins MJ, Harries LW, Wolf CR (1999). «Molecular genetics of the human cytochrome P450 monooxygenase superfamily.». Xenobiotica 28 (12): 1129-65. PMID 9890157.
- Meijerman I, Beijnen J, Schellens J. «Herb-drug interactions in oncology: focus on mechanisms of induction». Oncologist 11 (7): 742-52. PMID 16880233.
- Goldstein JA, de Morais SM (1995). «Biochemistry and molecular biology of the human CYP2C subfamily.». Pharmacogenetics4 (6): 285-99. PMID 7704034.
- Miners JO, Birkett DJ (1998). «Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.». British journal of clinical pharmacology 45 (6): 525-38. PMID 9663807.
- Smith G, Stubbins MJ, Harries LW, Wolf CR (1999). «Molecular genetics of the human cytochrome P450 monooxygenase superfamily.». Xenobiotica 28 (12): 1129-65. PMID 9890157.
- Henderson RF (2001). «Species differences in the metabolism of olefins: implications for risk assessment.». Chem. Biol. Interact. 135-136: 53-64. PMID 11397381.
- Xie HG, Prasad HC, Kim RB, Stein CM (2003). «CYP2C9 allelic variants: ethnic distribution and functional significance.». Adv. Drug Deliv. Rev. 54 (10): 1257-70. PMID 12406644.
- Palkimas MP, Skinner HM, Gandhi PJ, Gardner AJ (2004). «Polymorphism induced sensitivity to warfarin: a review of the literature.». J. Thromb. Thrombolysis 15 (3): 205-12. doi:10.1023/B:THRO.0000011376.12309.af. PMID 14739630.
- Daly AK, Aithal GP (2004). «Genetic regulation of warfarin metabolism and response.». Seminars in vascular medicine 3 (3): 231-8. doi:10.1055/s-2003-44458. PMID 15199455.
- García-Martín E, Martínez C, Ladero JM, Agúndez JA (2007). «Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals.». Molecular diagnosis & therapy 10 (1): 29-40. PMID 16646575.